Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kamada Ltd - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
KMDA
Nasdaq
2836
https://www.kamada.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kamada Ltd
KMDA: Double Digit Growth Anticipated in 2024 with $158 Million in Expected Revenues and $28 Million in Expected Adjusted EBITDA…
- Mar 13th, 2024 10:46 am
Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript
- Mar 7th, 2024 3:32 pm
Kamada Issues 2024 CEO Letter to Shareholders
- Mar 6th, 2024 12:05 pm
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
- Mar 6th, 2024 12:00 pm
Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024
- Feb 28th, 2024 12:00 pm
KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®
- Dec 7th, 2023 4:00 pm
KMDA: Amendment and Extension of Kedrab® U.S. Distribution Agreement to Generate at Least $180 Million Over First Four Years…
- Dec 7th, 2023 12:05 pm
Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years
- Dec 6th, 2023 12:00 pm
KMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds…
- Nov 15th, 2023 3:06 pm
Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance
- Nov 13th, 2023 12:00 pm
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
- Nov 8th, 2023 12:00 pm
Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data
- Oct 16th, 2023 11:00 am
Kamada Provides Corporate Update on its Israel Operations
- Oct 10th, 2023 11:37 am
Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds
- Aug 30th, 2023 11:00 am
KMDA: 2Q23 Revenues up 59% YoY; Reiterates 2023 Revenue Guidance of $138 Million to $146 Million…
- Aug 21st, 2023 1:40 pm
Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance
- Aug 16th, 2023 11:00 am
Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023
- Aug 9th, 2023 11:00 am
Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.
- Jul 12th, 2023 11:00 am
KMDA: 1Q23 Revenues of $30.7 Million; Continue to Expect 2023 Revenues of $138 Million to $146 Million…
- May 26th, 2023 10:10 am
Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance
- May 24th, 2023 11:10 am
Scroll